From the ∗Peter MacCallum Cancer Centre, Victoria, Australia
†Department of Pathology, GZA-ZNA, Antwerp, Belgium
‡University of Melbourne, Parkville, Australia.
Conflicts of Interest and Sources of Funding: R.S. reports nonfinancial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche for an advisory board related to a trial-research project. P.S.S. declares being an uncompensated consultant to Roche-Genentech. S.L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly, Nektar Therapeutics, Astra Zeneca, and Seattle Genetics; she has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca, and Roche-Genentech and as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Puma Biotechnology, Astra Zeneca, Silverback Therapeutics, and G1 Therapeutics. R.S. is supported by a grant from the Breast Cancer Research Foundation (BCRF, grant 17-194). S.L. is supported by Breast Cancer Research Foundation (BCRF) NY and the National Breast Cancer Foundation (NBCF) of Australia. For the remaining authors none were declared.
Reprints: Sherene Loi, PhD, Peter MacCallum Cancer Centre, University of Melbourne, 305 Grattan St., Melbourne, Victoria 3000, Australia. E-mail: [email protected].
